Serum-derived immunoglobulins alter amyloid β transport across a blood-brain barrier in vitro model

Pharmazie

Volumn 65, Issue 4, 2010, Pages 267-273

  Noe, C R ^a   Poetsch, V ^b   Bennani Baiti, B ^b   Neuhaus, W ^b   Muchitsch, E M ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOTHERAPY; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ALGORITHMS; AMYLOID BETA-PROTEIN; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNE SERA; IMMUNOGLOBULINS; PERMEABILITY; RATS; RECEPTORS, FC;

EID: 77950619309     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.9319     Document Type: Article

References (40)

1. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT (2001) Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7: 369-372.
2. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002) Passage of amyloid ß protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23: 2223-2226.
3. Banks WA, Pagliaric P, Nakaokea R, Morleya JE (2005) Effects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins. Peptides 26: 287-294.
4. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H (2000) Peripherally administered antibodies against amyloid ß-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919.
5. Bickel U (1995) Antibody delivery through the blood-brain barrier. Adv Drug Deliv Rev 15: 53-72.
6. Borvak J, Richardson J, Medesan C, Antohe F, Radul C, Simionescu M, Ghetie V, Ward ES (1998) Functional expression of the MHC classIrelated receptor, FcRn, in endothelial cells of mice. Int Immunol 10: 1289-1298.
7. Bouras C, Riederer BM, Kfvaria E, Hof PR, Giannakopoulosa P (2005) Humoral immunity in brain aging and Alzheimer's disease. Brain Res Rev 48: 477-487.
8. Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul SM, Hyman BT, Holtzman DM (2005) Anti- Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 115: 428-433.
9. Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, Venkataraman V, D'Andrea MR, Dinsmore S, Nagele RG (2007) Aβ peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 1142: 223-236.
10. Deane R, Wu Z, Zlokovic BV (2004) RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier. Stroke 35: 2628-2631.
11. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z (2005) IgG-assisted age-sependent clearance of Alzheimer's amyloid ß peptide by the blood-brain neonatal Fc receptor. J Neurosci 25: 11495-11503.
12. Dodel R, Hampel H, Depboylu, Lin S, Gao F, Schock S, Jäckel S, Wie X, Buerger K, Höft C, Hemmer B, Möller HJ, Farlow M, Oertel WH, Sommer N, Du Y (2002) Human antibodies against amyloid β peptide: a potential treatment for Alzheimer's disease. Ann Neurol 52: 253-256.
13. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nölker C, Möller HJ, Wie X, Farlow M, Sommer N, Oertel WH (2004) Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 1472-1474.
14. Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M (2003) Human anti-b-amyloid antibodies block b-amyloid fibril formation and prevent b-amyloid-induced neurotoxicity. Brain 126: 1935-1939.
15. Ellinger I, Schwab M, Stefanescu A, Hunziker W, Fuchs R (1999) IgG transport across trophoblast-derived BeWo cells: a model system to study IgG transport in the placenta. Europ J Immunol 29: 733-744.
16. Ellinger I, Reischer H, Lehner C, Leitner K, Hunziker W, Fuchs R (2005) Overexpression of the Human Neonatal Fc-receptor alpha chain in Trophoblast derived BeWo cells increased cellular retention of β2- microglobulin. Placenta 26: 171-182.
17. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, Lindmark T, Mabondzo A, Nilsson JE, Raub TJ, Stanimirovic D, Terasaki T, Öberg JO, Österberg T (2005) In vitro models for the blood-brain barrier. Toxicol in Vitro 19: 299-334.
18. Hack CE, Scheltens P (2004) Intravenous immunoglobulins: a treatment for Alzheimer's disease? J Neurol Neurosurg Psychiatry 75: 1374-1375.
19. Istrin G, Bosis E, Solomon B (2006) Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-b peptide. J Neurosci Res 84: 434-443.
20. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HTJ, Nixon RA, Mercken M, Bergeron C, Fraser PE, George-Hyslop P, Westaway D (2000) Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (6815): 979-982.
21. Jordan SC, Toyoda M, Vo AA (2009) Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 88: 1-6.
22. Kiessling F, Kartenbeck J, Haller C (1999) Cell-cell contacts in the human cell line ECV304 exhibit both endothelial and epithelial characteristics. Cell Tissue Res 297: 131-140.
23. Leitner K, Ellinger I, Grill M, Brabec M, Fuchs R (2006) Efficient apical IgG recycling and apicalto-basolateral Transcytosis in polarized BeWo cells overexpressing hFcRn. Placenta 27: 799-811.
24. Marco S, Skaper SD (2006) Amyloid beta-peptide 1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett 401: 219-224.
25. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardyk J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985.
26. Neuhaus W, Bogner E, Wirth M, Trzeciak J, Lachmann B, Gabor F, Noe CR (2006) A novel tool to characterize paracellular transport: the APTSdextran ladder. Pharm Res 23: 1491-1501.
27. NeuhausW, Plattner VE,Wirth M, Germann B, Lachmann B, Gabor F, Noe CR (2008) Validation of in vitro cell culture models of the blood-brain barrier: Tightness characterization of two promising cell lines. J Pharm Sci 97: 5158-5175.
28. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54.
29. PanW, Solomon B, Maness LM, Kastin AJ (2002) Antibodies to β-amyloid decrease the blood-to-brain transfer of β-amyloid peptide. Exp Biol Med 227: 609-615.
30. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (6740): 173-177.
31. Schenk D (2002) Opinion: Amyloid-beta immunotherapy for Alzheimer's Disease: the end of the beginning. Nat Rev Neurosci 3: 824-828.
32. Schlachetzki F, Zhu C, PardridgeWM(2002) Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 81: 203-206. (Pubitemid 34808868)
33. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-b1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106: 1489-1499.
34. Sigurdsson EM, Wisniewski T, Frangione B (2002) A safer vaccine for Alzheimer's disease? Neurobiol Aging 23: 1001-1008.
35. Simister NE and Mostov KE (1989) An Fc receptor structurally related to MHC class I antigens. Nature 337: 184-187.
36. Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer's Aβ peptide: the many roads to perdition. Neuron 43: 605-608.
37. Weksler ME, Gouras G, Relkin NR, Szabo P (2004) The immune system, amyloid-beta peptide, and Alzheimer's disease. Immunol Rev 205: 244-256.
38. Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice- Evans C (2003) Interaction between flavonoids and the blood-brain barrier: in vitro studies. J Neurochem 85: 180-192.
39. ZhangY, PardridgeWM(2001) Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 114: 168-172. (Pubitemid 32184738)
40. Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89: 807-811.